Our guest post, “Moving Beyond Mitigation: Cracking the Maximizer Code to Protect Patient Affordability,” is featured on Drug Channels, popular among industry insiders and outsiders for their expert insights and straightforward explanations of pharmaceutical economics and the drug distribution system.

This article written by our VP of Patient Affordability explores how traditional copay assistance models have failed to keep pace with the growing complexity of the patient affordability landscape. As maximizers now impact over 40% of commercially insured patients, legacy solutions have proven too slow, too rigid, and too fragmented to effectively safeguard affordability dollars. In contrast, a new generation of dynamic copay strategies are emerging — with increasing adoption among top pharma brands, the article outlines why this shift marks a critical turning point for the industry—and how dynamic systems are quickly becoming the new standard.

To read the full piece, click here.